Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.45 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8179952 | 0.93 | KDM4E (0.60) | KDM4EPOLBHPGDGAAKMT2A | |
| SCHEMBL7651531 | 0.87 | GAA (0.51) | KDM4EHPGDGAAKMT2AMEN1 | |
| SCHEMBL7646320 | 0.80 | MEN1 (0.67) | KDM4EPOLBHPGDGAAKMT2A | |
| SCHEMBL7648688 | 0.79 | KMT2A (0.50) | KDM4EPOLBHPGDGAAKMT2A | |
| SCHEMBL8187562 | 0.79 | GAA (0.56) | KDM4EGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL17007445 | 0.78 | POLB (0.61) | KDM4EPOLBHPGDGAAKMT2A | |
| SCHEMBL7645943 | 0.78 | GAA (0.46) | KDM4EHPGDGAAKMT2AMEN1 | |
| SCHEMBL7647926 | 0.77 | KMT2A (0.55) | KDM4EPOLBHPGDGAAKMT2A | |
| SCHEMBL7652256 | 0.76 | MEN1 (0.72) | POLBKMT2AMEN1ALDH1A1AKR1C3 | |
| SCHEMBL15014564 | 0.74 | KDM4E (0.68) | KDM4EPOLBHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | claimed |
| US-6486173-B2 | SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | disclosed |
| US-6239143-B1 | TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. | DUPONT PHARMACEUTICALS COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000000472-A1 | 5-HT7 RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | KDM4E 3671/4885POLB 3434/4885HPGD 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.